INGRAM DOUGLAS S 4
4 · Sarepta Therapeutics, Inc. · Filed Nov 6, 2023
Insider Transaction Report
Form 4
INGRAM DOUGLAS S
DirectorPresident & CEO
Transactions
- Purchase
Common Stock
2023-11-03$80.33/sh+3,884$312,002→ 390,107 total - Purchase
Common Stock
2023-11-03$78.57/sh+10,081$792,064→ 375,163 total - Purchase
Common Stock
2023-11-03$79.70/sh+11,060$881,482→ 386,223 total - Purchase
Common Stock
2023-11-03$81.26/sh+200$16,252→ 390,307 total
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $78.03 to $79.02, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
- [F2]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $79.05 to $80.05, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
- [F3]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $80.08 to $80.96, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.